These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Micrometastases in patients with colorectal cancer: markers for metastatic potential or proofs for residual disease]. Iovchev I; Trifonov D; Popkharitov A; Khadzhipetkov F; Nikolov S Khirurgiia (Sofiia); 2004; 60(4-5):18-21. PubMed ID: 16042058 [TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease: relevance for diagnosis and treatment of human malignancies. Hirsch-Ginsberg C Annu Rev Med; 1998; 49():111-22. PubMed ID: 9509253 [TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of minimal residual disease in autologous bone marrow transplantation]. Jørgensen H; Bukh A; Hokland P; Ellegaard J; Madsen PS; Hokland M Nord Med; 1996 Dec; 111(10):344-7. PubMed ID: 8992466 [TBL] [Abstract][Full Text] [Related]
5. First international ISHAGE symposium on minimal residual cancer. Pantel K; Moss TJ J Hematother; 1996 Oct; 5(5):511-7. PubMed ID: 8938523 [No Abstract] [Full Text] [Related]
6. [Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications]. Toi M; Matsumoto G Gan To Kagaku Ryoho; 2000 Aug; 27(9):1315-36. PubMed ID: 10969586 [TBL] [Abstract][Full Text] [Related]
13. [Psychological adaptation to bone marrow transplantation]. Delvaux N Rev Med Brux; 1992 Jun; 13(6):219-22. PubMed ID: 1631421 [TBL] [Abstract][Full Text] [Related]
14. [Molecular cytogenetic monitoring of chimerism and minimal residual disease in patient with chronic myeloid leukemia after allogenic and syngenic bone marrow transplantation]. Vinogradova OA; Savchenko VG; Domracheva EV; Liubimova LS; Ol'shanskaia IuV; Diachenko LV; Parovichnikova EN; Mendeleeva LP; Zakharova AV Ter Arkh; 2002; 74(7):38-44. PubMed ID: 12181833 [TBL] [Abstract][Full Text] [Related]
15. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Grimwade D; Tallman MS Leuk Res; 2011 Jan; 35(1):3-7. PubMed ID: 20674017 [No Abstract] [Full Text] [Related]
16. [The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications]. Faulkner LB; Tamburini A; Tintori V; Paoli A; Tondo A; Bernini G; Medicina D; Brisigotti M; Corrias MV; Scaruffi P; Rosanda C; Lo Piccolo MS; Viscardi E; Milanaccio C; Garaventa A; De Bernardi B Pediatr Med Chir; 1998; 20(3):175-8. PubMed ID: 9744008 [TBL] [Abstract][Full Text] [Related]
17. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. Mizuta S; Ito Y; Kohno A; Kiyoi H; Miyamura K; Tanimoto M; Takamatsu J; Naoe T; Morishima Y; Ueda R; Saito H Bone Marrow Transplant; 1999 Oct; 24(7):777-84. PubMed ID: 10516682 [TBL] [Abstract][Full Text] [Related]
18. Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging. Negrin RS J Hematother; 1992; 1(4):361-8. PubMed ID: 1345678 [TBL] [Abstract][Full Text] [Related]
19. Quality of life and difficulties of patients encountered after autologous stem cell transplantation. Kav S; Aslan O; Tekin F; Yesil H; Meral C; Ozturk U; Bulut Z; Enaboifo A; Yazar B J BUON; 2009; 14(4):673-80. PubMed ID: 20148461 [TBL] [Abstract][Full Text] [Related]
20. The role of cytokines following bone marrow transplantation: indications and controversies. Weinthal JA Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S10-4. PubMed ID: 8971400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]